Meeder Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Meeder Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-107	Closed	-$6K	–	2433
2020 Q2	$6K	Sell	107 -115	-52%	-$6.49K	﹤0.01%	1493
2020 Q1	$12K	Sell	222 -10	-4%	-$746	﹤0.01%	1451
2019 Q4	$17K	Hold	232	–	–	﹤0.01%	1419
2019 Q3	$23K	Buy	232 +135	+139%	+$13.8K	﹤0.01%	1262
2019 Q2	$13K	Buy	97 +89	+1,113%	+$13.7K	﹤0.01%	1388
2019 Q1	$1K	Buy	+8	New	+$1.19K	﹤0.01%	1655

Other funds holding ONCT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

AAM

Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return

Meeder Asset Management's ONCT Position: Q3 2020 in Review

Meeder Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2020, closing a stake of 107 shares — an estimated $6K sold.

Meeder Asset Management first reported a position in ONCT in Q1 2019 and held it in 6 quarters. The position peaked at $23K in Q3 2019. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2020.

Meeder Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Meeder Asset Management sold 107 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $6K.
Meeder Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2019 and held it in 6 quarters.
Meeder Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $23K in Q3 2019.
23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.